TransMedics Group, Inc.

How big is TransMedics Group, Inc.?

As of Jun 18, TransMedics Group, Inc. has a market capitalization of $4.61 billion, with net sales of $488.23 million and a net profit of $48.95 million over the last four quarters. Shareholder's funds are $228.60 million, and total assets amount to $828.43 million.

Market Cap: As of Jun 18, TransMedics Group, Inc. has a market capitalization of 4,608.16 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 488.23 million and a net profit of 48.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 228.60 million, while total assets were reported at 828.43 million.

What does TransMedics Group, Inc. do?

TransMedics Group, Inc. is a medical technology company specializing in organ transplant therapy for patients with end-stage organ failure. As of March 2025, it reported net sales of $144 million and a net profit of $26 million, with a market cap of approximately $4.6 billion.

Overview:<BR>TransMedics Group, Inc. is a commercial-stage medical technology company focused on developing organ transplant therapy for end-stage organ failure patients within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 144 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 26 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4,608.16 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 96.00 <BR>Debt Equity: 0.76 <BR>Return on Equity: 18.38% <BR>Price to Book: 17.30 <BR><BR>Contact Details:<BR>Address: 84 State St, BOSTON MA: 02109-2202 <BR>Tel: 1 978 5520900

Should I buy, sell or hold TransMedics Group, Inc.?

Who are in the management team of TransMedics Group, Inc.?

As of March 2022, the management team of TransMedics Group, Inc. includes Mr. James Tobin (Independent Chairman), Dr. Waleed Hassanein (CEO), and several independent directors: Ms. Merilee Raines, Mr. Edward Basile, Mr. Thomas Gunderson, Mr. Edwin Kania, and Dr. David Weill. They oversee the company's strategic direction and operations.

As of March 2022, the management team of TransMedics Group, Inc. includes the following individuals:<BR><BR>- Mr. James Tobin, Independent Chairman of the Board<BR>- Dr. Waleed Hassanein, President, Chief Executive Officer, and Director<BR>- Ms. Merilee Raines, Director<BR>- Mr. Edward Basile, Independent Director<BR>- Mr. Thomas Gunderson, Independent Director<BR>- Mr. Edwin Kania, Independent Director<BR>- Dr. David Weill, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is TransMedics Group, Inc. technically bullish or bearish?

As of October 31, 2025, TransMedics Group, Inc. shows a bullish trend supported by positive MACD and moving averages, despite mixed signals from the KST and a recent price decline, with impressive year-to-date and five-year returns compared to the S&P 500.

As of 31 October 2025, the technical trend for TransMedics Group, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, which slightly tempers the overall bullish outlook. The Bollinger Bands are mildly bullish on both weekly and monthly charts. <BR><BR>Despite a recent decline in price, the stock has demonstrated strong performance over longer periods, with a year-to-date return of 96.01% compared to the S&P 500's 16.30%, and a five-year return of 870.69% versus the S&P 500's 109.18%. Overall, the current technical stance is bullish, albeit with some mixed signals from the KST.

Is TransMedics Group, Inc. overvalued or undervalued?

As of November 7, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96 and a year-to-date return of 96.30%, outperforming the S&P 500, despite having a higher P/E than CONMED Corp. and a lower EV to EBITDA than Integer Holdings Corp.

As of 7 November 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22, which suggest that while the stock is not undervalued, it is also not excessively priced compared to its recent valuation history.<BR><BR>In comparison to its peers, TransMedics has a significantly higher P/E ratio than CONMED Corp., which stands at 19.96, and a lower EV to EBITDA than Integer Holdings Corp. at 41.17. This indicates that while TransMedics may be on the higher end of the valuation spectrum, it still holds a competitive position within its industry. Notably, the stock has outperformed the S&P 500 with a year-to-date return of 96.30% compared to the S&P 500's 14.40%, reinforcing the notion that the market recognizes its growth potential.